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Background: Preclinical studies suggest a role for lysophosphatidic acid (LPA) in the 
pathogenesis of systemic sclerosis (SSc).  
 
Objectives: SAR100842, a potent selective oral antagonist of LPA1 receptor, was assessed 
for safety, biomarkers and clinical efficacy in patients with diffuse cutaneous SSc (dcSSc).  
 
Methods: An 8-week double-blind, randomized, placebo-controlled study followed by a 16-
week open label extension with SAR100842 was performed in patients with early dcSSc and 
a baseline Rodnan skin score (mRSS) of at least 15. The primary endpoint was safety 
during the double-blind phase of the trial. Exploratory endpoints included the identification of 
a LPA-induced gene signature in patients ‘skin. 
 
Results: 17 of 32 subjects were randomized to placebo and 15 to SAR100842; 30 patients 
participated in the extension study. The most frequent adverse events reported for 
SAR100842 during the blinded phase were headache, diarrhea, nausea and fall and the 
safety profile was acceptable during the extension part. At Week 8, mean reduction in mRSS 
was numerically greater in the SAR100842 compared to placebo (mean change [SD]: -3.57 
[4.18] versus -2.76 [4.85]; difference [95% CI]: -1.2 [-4.37 to 2.02], p=0.46). A greater 
reduction of LPA related genes was observed in skin of SAR100842 group at Week 8, 
indicating LPA1 target engagement.  
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Conclusion: SAR100842, a selective orally available LPA1 receptor antagonist, was well 
tolerated in patients with dcSSc. MRSS improved during the study although not reaching 
significance, and additional gene signature analysis suggested target engagement. These 
results need to be confirmed in a larger controlled trial. 
 
Clinicaltrials.gov NCT01651143 
 
Systemic sclerosis (SSc) is characterized by fibrosis of the skin and internal organs, 
prominent alterations of the microvasculature, and frequent abnormalities of cellular and 
humoral immunity (1). SSc is an orphan disease, with high morbidity, which strongly impairs 
the quality of life and has a high case-specific mortality (2). The high burden of severe skin 
and internal organ involvement in the early stages of diffuse cutaneous SSc (dcSSc) has 
been highlighted by many cohort studies. Safe and effective treatments for skin and other 
manifestations of dcSSc are lacking (3). 
 
The pathogenesis of SSc is complex and at present there is no unifying theory that may 
explain all its aspects. Consensual models of pathogenesis have suggested that early 
vascular events associated with autoimmunity and inflammation lead to fibroblast activation 
and differentiation, promoting subsequent fibrosis. A broad range of biological processes 
interact in SSc and these include involvement of key profibrotic cytokines and growth 
factors, an imbalance in Th1/Th2/Th17/Treg systems promoting inflammation and fibrosis 
and activation of B cells promoting production of autoantibodies (1). 
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Lysophosphatidic acid (LPA) is a lipid mediator that signals through specific G-protein-
coupled receptors, designated as LPA1 to LPA6. It is generated at sites of inflammation or 
cell injury by the action of lysophospholipase D (lysoPLD), also known as autotaxin, on 
lysophosphatidylcholine and other lysophospholipids (4). LPA exerts various physiological 
effects on the receptors of parenchymal cells with some tissue specificities with regards to 
the various receptors (5, 6, 7). LPA mediates a variety of cell activities, including 
mitogenesis, cell differentiation, cell survival, cytoskeletal reorganization, cell migration and 
extracellular matrix production. Recent studies looking at circulating markers, in vitro cell 
activation, or animal models have suggested that LPA is involved, and plays an important 
role, in the pathogenesis of SSc. The role of LPA has also been demonstrated in several 
animal models of organ fibrosis independently of SSc (8-11).  
 
SAR100842 is a potent selective LPA1 receptor antagonist (Sanofi R&D, France). In vivo, 
SAR100842 reversed dermal thickening and significantly inhibited myofibroblast 
differentiation and collagen content in mouse skin fibrosis model. Similar anti-fibrotic 
properties were observed using the Tsk-1 mouse model (Illiano et al, submitted). 
Mechanistic investigations showed that the anti-fibrotic effects of LPA1 blockade could be 
mediated partly via inhibition of the Wnt signaling pathway. 
 
Taking into account the promise of LPA1 receptor blockade in fibrotic pre-clinical models and 
the unmet need of early dcSSc, we performed a randomized proof-of-biological activity study 
assessing the effects of SAR100842 in early dcSSc patients.  
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PATIENTS AND METHODS 
Study design 
This was a double-blind, randomized, placebo-controlled, 8-week Phase 2a study, followed 
with an open label extension for 16 weeks (Supplemental Figure 1).  
 
The objective was to investigate the effects of orally administered SAR100842 in patients 
with dcSSc, to characterize safety, plasma pharmacokinetics (PK) and pharmacodynamics 
(PD) with a focus on clinical efficacy and on SSc related biomarkers. In the double-blind 
phase of the study, SAR100842 300 mg (100 mg + 200 mg tablets for a total daily dose of 
600 mg) or matching placebo were administered orally twice a day.  
 
Following a screening period of up to 14 days, eligible patients were randomized. Clinical 
and biological parameters were assessed and skin biopsies were taken at a pre-defined 
area of the forearm at baseline and end of treatment (Week 8).  
 
Patients who had completed the 8-week treatment and who did not meet any discontinuation 
criterion (see supplement) were invited to participate in the open label non-controlled 16-
week extension phase of the study with the same dosage of SAR100842 as in the initial part 
of the trial. 
 
Patients were evaluated at the end of the extension part (Week 24) for clinical and biological 
assessments including two additional skin biopsies in consenting patients. 
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The dose of 300 mg BID was selected for the study based on activity/efficacy data from in 
vitro pharmacology models and in vivo animal disease models, as well as the safety profile 
observed in healthy volunteers (unpublished data). 
 
The duration of 8-week was chosen based on expert opinion, suggesting that an 8-week 
treatment duration would be sufficient to demonstrate significant changes in SSc-related 
biomarkers. This design reduced the exposure of dcSSc patients to an experimental drug in 
this phase 2a study, while it provided the necessary data on safety and activity to support a 
full development in this indication.  
 
A total of 12 active clinical sites located in Switzerland, France, UK, Italy, and USA 
participated in this study. 
 
Patients 
Patients met the 1980 American College of Rheumatology (ACR) classification criteria for 
SSc, with diffuse cutaneous involvement (12), and had less than 36-month disease duration 
since the onset of first SSc manifestation other than Raynaud’s phenomenon. A baseline 
modified Rodnan skin score (mRSS) ≥ 15/51 together with an area of definite involvement of 
the mid-volar forearm allowing 4 mm skin biopsies were other key inclusion criteria. 
 
Immunosuppressive therapies stable for 4 weeks prior to enrollment were permitted 
including prednisolone up to 10 mg/d, methotrexate up to 25 mg/week, azathioprine up to 
100 mg/d and mycophenolate mofetil up to 2 g daily (see protocol in supplement for 
definition).  
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Patients experiencing orthostatic hypotension (postural reduction of systolic blood pressure 
by >20 mm Hg or reduction of diastolic blood pressure by >10 mm Hg), moderate to severe 
postural dizziness, pre-syncope or syncope within the last 6 months of screening were 
excluded, related to the current knowledge of the study drug obtained in phase 1 studies.  
 
Study endpoints 
The primary endpoint was safety and tolerability during the 8-week treatment period. 
Secondary endpoints were: change from baseline to Week 8 in skin and blood biomarkers, 
changes from baseline to Week 8 in the mRSS and SHAQ, safety and tolerability during the 
extension treatment period and pharmacokinetics. Skin biopsies were used for RNA 
extraction and some mRNA biomarkers were assessed using quantitative PCR including: 
cartilage oligomeric matrix protein (COMP), thrombospondin 1 (THBS1), Plasminogen 
Activator Inhibitor type 1 (PAI-1), Wingless-Type MMTV integration site family member 2 
(Wnt2) and secreted frizzled-related protein 4 (SFRP4). Other skin biopsies were dedicated 
to immunohistochemistry (IHC). Labeling for α-SMA was performed on serial slides and skin 
thickness (histology) was evaluated. LPA markers were selected based on literature data 
and internal confirmation using dermal fibroblasts from SSc patients treated with LPA. The 
choice of other markers (COMP, THBS1, Col1 and SMA) was based on literature data 
selecting genes or proteins that may play a key role in the evolution of fibrosis in SSc 
patients (13, 14). 
 
To explore the effect of SAR100842 on the LPA pathway, we used the results of a parallel 
study performed using cultured dermal fibroblasts from patients with SSc. LPA gene 
expression response was defined in the cultured dermal fibroblasts study. This LPA 
response was used in combination with the expression profile in patient skin biopsies for 
identifying a LPA signature, according to a guided clustering algorithm. The goal of using 
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this data integration approach was to ensure that the identified gene cluster with high LPA 
treatment response was also consistently expressed and correlated in skin biopsies. 
 
The identified fibroblast LPA signature was subsequently reduced to a single composite 
biomarker called pathway activation index (PAI) computed as coefficient of a robust 
regression on the expression matrix of the LPA signature at each treatment visit (median 
polish) (15). PAI was then used as a surrogate biomarker for investigating SAR100842 
treatment response. 
 
Exploratory endpoints were change from baseline to Week 24 in the mRSS and SHAQ, and 
also the change in pain or pruritus from baseline to Week 8 and Week 24. 
 
Statistical methods 
Sample size determination 
No formal sample size calculation was performed for this proof of biological activity study 
and the sample size for this study was based upon empirical considerations. 
 
Safety analyses 
The safety analyses were based on the safety population of all randomized patients who 
actually received at least 1 dose of the IMP, and analyzed according to the treatment 
actually received in the core part or extension part. The safety analyses were descriptive. 
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Efficacy analyses 
The efficacy analyses were based on the modified intent-to-treat (mITT) population, of all 
randomized population who actually received at least 1 dose of IMP and with at least 1 post-
IMP-administration measurement during the blinded period (double-blind phase). The mITT 
population for the extension part was defined as randomized population who did actually 
receive at least 1 dose of IMP in the extension part with at least 1 post-IMP administration 
measurement during the extension part. 
 
An analysis of covariance (ANCOVA) was performed for the total mRSS score and HAQ-DI 
on the change from baseline to Week 8 on the mITT population, with treatment group as the 
main factor and the baseline score centered on its means in the mITT population as a 
continuous covariate. Student-t test was used to determine the superiority of SAR100842 
300 mg BID over placebo at Week 8 with nominal 2-sided type I error rate of 5%. 
 
The analysis of other SHAQ variables was purely descriptive. 
 
All other secondary endpoints were described by treatment and analyzed within an 
ANCOVA. 
 
Biomarker analyses 
The biomarker analyses were based on the population of all randomized and treated 
patients who received at least 4 weeks of study drug with at least a baseline and a post-
baseline assessment. Prior to all statistical analyses, mRNA data were normalized.  Each 
biomarker was analyzed using descriptive statistics. For each of the following skin 
A
cc
ep
te
d 
A
rt
ic
le
  
This article is protected by copyright. All rights reserved. 
biomarkers related to the disease: COMP, THBS1, Collagen 1A1 (COL1A1) mRNAs and α-
SMA labeling (13), the change from baseline to Week 8 measurement was analyzed using a 
rank ANCOVA, with treatment group as fixed effect and baseline value as covariate. 
 
Target engagement 
SSc fibroblasts were prepared from forearm biopsies, following established outgrowth 
conditions, and cultured in F-12K medium with 10% heat-inactivated fetal calf serum (FCS), 
100 units/ml of penicillin, 100μg/ml of streptomycin, and 0.3 mg/ml of L-glutamine. Dermal 
fibroblasts from healthy volunteers (N=4) and SSc patients (N=10) were seeded and treated 
with LPA at 10μM for 24h (vs vehicle). Supernatants were removed and cells were rinsed, 
stored and total RNA was purified using RNeasy Mini kit (Qiagen). The same methodology 
was used to extract RNA from skin biopsies from patients of the ACT study. Gene 
expression was measured by whole transcriptome profiling analysis using Affymetrix HG-
U133 plus 2.0 GeneChips. From each GeneChip result, a probe cell intensity data file (CEL 
file) was computed and represented an individual gene expression profile. Samples were 
clustered based on Euclidean distance and correlation for evaluating the similarity of the 
quality of each array against the quality of the other arrays. Principal component analysis 
(PCA) on expression data was performed as well as PCA on quality control metrics of the 
raw data provided by the Affymetrix platform (R-package simpleaffy). 
 
The guided clustering algorithm (15) was used for the identification a set of genes with high 
LPA perturbation in the cell culture study and that were consistently expressed in the skin 
biopsies of patients with SSc. A logistic regression model was computed for each probeset 
separately, with the LPA treatment label as outcome variable (LPA=1, Placebo=0) and the 
probeset as independent variable. Each model was adjusted by the fibroblasts type 
(normal/SSc). The coefficient of the probeset in the model was used as LPA activation 
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strength for weighting the probesets. The obtained weights were used in conjunction with the 
expression profile in skin biopsies at baseline to extract the LPA signature. The LPA 
signature was condensed into one surrogate marker called PAI. 
 
Descriptive statistics of change in LPA PAI from baseline to end of 8-week treatment were 
computed by treatment arm. The difference between SAR100842 and placebo was 
investigated using the model:  ∆PAI main part=β0 +β1 *treatment+β2 
*scaled_baselinePAI+ξ. 
 
Targeted gene expression analysis of selected LPA related and fibrosis genes was carried 
out in the same skin biopsy samples using RT-qPCR. 
 
Ethical approval 
The protocol and its amendments were submitted to independent Ethics Committees and/or 
Institutional Review Boards for review and written approval. All patients provided written 
Informed consent prior to the conduct of any study-related procedures, and the optional skin 
biopsy informed consent form (ICF) was obtained from patients who agreed to the collection 
of skin biopsy. 
 
In addition, dermal fibroblasts were grown from skin biopsies of another cohort of SSc 
patients fulfilling the ACR/EULAR classification criteria. Procedure was approved by the 
local ethics committee (University of Naples) and patients signed informed consent forms. 
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RESULTS 
Baseline characteristics of the patients 
Of 48 patients screened, 16 patients were screen failures (33.3%). Thirty-two (32) patients 
were randomized into the study: 15 received 300 mg SAR100842 twice a day and 17 
received placebo for 8 weeks. Patients across treatment groups had comparable 
demographic characteristics at baseline consistent with the overall population of dcSSc 
patients (Table 1). 
 
One patient in the SAR100842 group discontinued treatment on personal request but was 
included in the mITT analysis. Of the 32 patients initially randomized to the double-blind part, 
30 were enrolled into the extension part: Sixteen (16) and 14 patients initially treated with 
placebo or SAR100842, respectively, participated in the extension part. One patient in the 
placebo/SAR100842 group and 1 patient in the SAR100842 /SAR100842 group 
discontinued the treatment due to adverse events, and withdrew upon patients’ request. 
 
The mean overall compliance was comparably high among treatment groups (99.6% in the 
placebo versus 98.5% in the SAR100842 group). 
 
Safety: SAR100842 showed good tolerability 
Overall, SAR100842 was well tolerated: The detailed AE are described in supplementary 
material (Table S1). A total of 80% patients in the SAR100842 versus 71% patients in the 
placebo group reported at least one treatment emergent adverse event (TEAE). However, 
most of the TEAEs were mild to moderate in intensity. There was 1 treatment-emergent 
serious adverse event (SAE) in the SAR100842 group (syncope) in a patient with a medical 
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history of syncope in childhood. In the extension phase, two (2) patients reported a 
treatment-emergent SAE, one in each group. Dyspnea was reported in 1 patient 6 days after 
switching from placebo to SAR100842, and was considered to be related to the 
investigational medicinal product, while an infected digital ulcer in another patient was not 
considered to be drug-related. Two (2) patients prematurely discontinued due to TEAEs, 1 
for moderate arthritis in the SAR100842/SAR100842 group and 1 for pruritus, skin 
discoloration and swelling of face edema in the placebo/SAR100842 group.  
 
With regard to the laboratory safety assessments, no safety concern has emerged from the 
various laboratory parameters (Table S2, in supplementary documents). 
 
Efficacy: change in mRSS during the controlled and extension phases 
Primary analysis was conducted in mITT population on patients who were under treatment 
until Week 8. There was a numerically greater decrease without reaching statistical 
significance in the total mRSS score from baseline in the SAR100842 group compared to 
placebo (mean change [SD]: -3.57 [4.18] vs -2.76 [4.85]; treatment effect: -1.2; 95% CI [-
4.37 to 2.02], p=0.46; median change: -4 (Q1:Q3=-5:-1) versus -1.00 (Q1:Q3=-5:0) 
respectively) (Figure 1). 
 
After 24 weeks of treatment, patients in the SAR100842/SAR100842 group experienced a 
clinically meaningful decrease in total mRSS score (mean change [SD]: -7.36 [4.24]; median 
change = -7.50) versus baseline, and a high rate (78.6%) of patients improved by at least 5 
points (responder). Patients initially receiving 8 weeks of placebo also demonstrated an 
improvement in mRSS (mean change [SD]: -7.31 [4.59]; median change from baseline= -
7.00) after 24 weeks, with a responder rate of 69.2%.  
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Changes in quality of life during the controlled and extension phases 
There was no statistically significant difference in change of HAQ-DI total score from 
baseline to Week 8 between SAR100842 and placebo (mean change [SD]: 0.00 [0.33] in 
placebo and -0.14 [0.30] in SAR100842; treatment effect: -0.1; 95% CI [-0.38 to 0.09]). 
However, it can be pointed out that the mean absolute difference observed in the 
SAR100842 group (-0.14) versus baseline reached clinically meaningful level; indeed, an 
improvement of ≥0.14 of HAQ-DI is considered to be the minimum clinically important 
difference in patients with SSc. The improvement seen in the mean HAQ-DI total score was 
clinically significant from baseline to Week 24 compared to Week 8 in both the 
placebo/SAR100842 and the SAR100842 /SAR100842 group (mean change [SD]: -0.23 
[0.30] and -0.15 [0.33], respectively), and the percentage of patients who decreased by ≥ -
0.14 on the HAQ-DI total score in the 2 groups were comparable. 
 
Effects on pruritus and pain during the controlled and extension phases 
Based on preclinical rationale, LPA receptor antagonists may be effective on pruritus. 
Interestingly, despite a low baseline value, there was a numerical improvement in 
SAR100842 versus worsening in the placebo group (mean change [SD]: -0.37 [3.92] versus 
0.25 [1.79]) in the severity of pruritus using VAS assessed by patients from baseline to 
Week 8 (on 0-10 scale). Similarly, a reduced score in pruritus in patients with SAR100842 
/SAR100842 versus placebo/SAR100842 treatment was observed (mean change [SD]: -
1.38 [2.85] versus -0.84 [1.67]). The severity of pruritus was further decreased in patients 
with SAR100842 or initially treated with placebo at Week 24 compared to Week 8. The 
severity of pain using Numerical Pain Scale assessed by patients was low at baseline in the 
study population. No conclusion could be drawn. 
 
A
cc
ep
te
d 
A
rt
ic
le
  
This article is protected by copyright. All rights reserved. 
Biomarker endpoints: changes did not reach significance for skin fibrosis markers 
There was no statistically significant differential expression of any skin mRNA and protein 
biomarkers nor blood protein biomarkers between placebo and SAR100842. Alpha SMA and 
collagen Type 1 were used as fibrosis markers and were not modulated by the treatment 
(Figure 2) Disease signature was evaluated using either the four-gene biomarker as 
described by Farina et al or a combination of THBS1 and COMP. None of these genes 
change was correlated with the change in mRSS (Table 2). However, there was a trend for 
reduction in THBS1, after 8 weeks of SAR100842 compared to placebo although not 
reaching statistical significance (Figure 3). In addition, MS4A4A gene (a marker of M2 
macrophages) was also evaluated. The expression of this marker such as the 2-gene 
signature (14) were not modulated by SAR100842 and was not correlated with the change in 
mRSS (not shown). 
 
Global change in gene expression in skin samples at 8 weeks between vehicle and treated 
patients was evaluated using stringent cut-off for false discovery rate (0.05) or less stringent 
criteria (0.1). No significant difference was observed in any conditions. Data obtained for cut-
off of false discovery rate of <0.1 are presented in Table S3. 
 
SAR100842 induced target engagement in LPA pathway 
There was a numerical reduction without reaching statistical significance from baseline of 
some LPA-pathway biomarkers (PAI-1, Wnt2 and SFRP4) in SAR100842 versus placebo 
group (Figure 4). Although not significant the decrease of these biomarkers is of interest 
since they have been shown to be regulated by LPA and SAR100842 in dermal fibroblasts 
of SSc patients. Thus, a post-hoc analysis was performed to identify a more global LPA 
signature in dermal SSc fibroblasts and skin biopsies and to evaluate the impact of 
SAR100842 on this signature in patient skin to assess target engagement. 
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The signature was identified using both microarray data obtained in SSc dermal 
fibroblast treated for 24 hours with LPA and microarray data from skin biopsies of 
SSc patients at baseline. A guided clustering method was performed to give weight 
to genes that were expressed at significant level following LPA treatment but that 
were also expressed at a significant level in skin biopsies. This led to a list of 47 
genes identified as LPA signature provided in the supplementary document (Table 
S4). This signature reflects pathways, like proliferation, EGF signaling known to be 
mechanistically part of LPA responses in other cell types. These genes were 
reduced to a unique surrogate biomarker in one dimension called PAI using the 
median polish algorithm (16). The PAI was extracted as row effect as it represents 
the summary expression in each patient. A significant decrease in PAI was observed 
in the SAR100842 group (P-value = 0.0089) (Figure 5). 
 
DISCUSSION  
LPA is a phospholipid growth factor targeting cells through a number of cell surface 
receptors that has been implicated in the pathogenesis of SSc. Of the most interest, it has 
appeared as a possible mechanism contributing to excessive tissue fibrosis, mainly through 
LPA1 receptor activation (17), as observed in SSc. Recent findings further emphasis on the 
key role of autotaxin, and LPA axis in SSc (18). SAR100842 is a low molecular weight, 
selective inhibitor of LPA1 receptor, being developed as a potential novel therapy for SSc 
with the aim of reducing or even reversing the progression of fibrosis. This phase II study 
was the first to assess oral administration of SAR100842 in patients with early diffuse SSc.  
 
The safety and tolerability of SAR100842 was the primary outcome and SAR100842 was 
shown to be well tolerated in patients with dcSSc.  
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In pre-clinical studies, the administration to rats at doses up to 2000 mg/kg/day caused no 
toxicologically relevant effects. Compound related findings were limited to a slightly higher 
incidence of regurgitation in females at high dose and the present study did not show any 
specific gastro-intestinal adverse events in SSc patients. In previous phase I studies, the 
safety profile was very good and overall, the most frequently reported related adverse 
events were headache, symptomatic orthostatic hypotension or postural dizziness, and 
flatulence. Those adverse events were not severe or serious. In the present study both in 
the short-term double-blind and the longer-term open part, no safety signal emerged on vital 
signs, orthostatic hypotension, ECG, or laboratory parameters. A common toxicological 
concern with anti-fibrotic agents is whether patients may exhibit a delay in normal wound 
healing. Studies with LPA receptor antagonists have been reassuring using incisional and 
excisional wounding studies in rats (18), but it is noteworthy that in the present study, 
despite one third of the patients had digital ulcerations at baseline, no overt safety concerns 
emerged for them, confirming the good safety profile in SSc patients.  
 
The clinical efficacy of SAR100842 was part of the secondary endpoints but no effect was 
expected on the mRSS after 8 week of treatment because mRSS is slow in changing. 
Nevertheless, at the end of the double-blind period, a numerically greater decrease in total 
mRSS score from baseline in the SAR100842 group compared to placebo was detected 
without reaching statistical significance (treatment effect: -1.2; 95% CI [-4.37 to 2.02]; 
median change SAR100842 versus placebo: -4.00 versus -1.00, respectively). Also, there 
was a numerical greater reduction without reaching statistical significance in the HAQ-DI 
(treatment effect: -0.1; 95% CI [-0.38 to 0.09]) in the SAR100842 group versus placebo. 
These findings are promising; they might be due to the mechanism of action of SAR100842 
and/or may also be explained by a large proportion of subjects on background 
immunosuppressive medications. These findings were supportive of the effect observed 
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after 24 weeks of treatment where patients experienced a clinically meaningful decrease in 
total mRSS score (median change= -7.5) with a high responder rate of 78.6% for patients 
improved by at least 5 points (19) versus baseline and similar benefit was observed in the 
HAQ-DI. Although being secondary end-points and with weak statistical power, the size of 
the decrease must be underlined and is larger than that observed in other trials targeting the 
same SSc population. Furthermore, the similar trend observed for skin changes and quality 
of life is encouraging and promising for future trials. Nevertheless, and despite being 
encouraging, the open label data should be interpreted with caution.  
 
This study must be interpreted taking into account its limitations. The sample size was not 
large, but in line with the design of a proof-of biological activity study looking primarily at 
safety. The duration may be considered as short and most trials are expected to last more 
than 6 months but the observed changes of mRSS in this population are promising. SSc is a 
systemic disease and organ involvement defines the prognosis. No data could be provided 
on organ involvement from the present study and this will have to be addressed in the future.  
 
Pharmacodynamic and biomarker assessments were part of the secondary endpoints. There 
was no statistically significant differential expression of any biomarker between the 2 groups 
of patients. The response rate was higher than expected (20%) in the placebo group, while 
the response rate in the SAR100842 group was in the initial assumption range (60%).  
 
Using a new unbiased statistical analysis, a guided clustering algorithm allowed the 
identification of a set of genes with high LPA perturbation in the cell culture study and that 
were consistently expressed and correlated with similar expression in skin samples from 
patients. This LPA signature was then reduced to one dimension and change in the resulting 
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PAI was computed in skin biopsies of patients treated with placebo vs patients treated with 
SAR100842. A significant effect of SAR100842 on change from baseline for PAI was 
indicative of an effect of SAR100842 on the LPA signature (15 patients per treatment arm) 
demonstrating target engagement upon SAR100842 treatment for 8 weeks.  
 
The optimal clinical trial duration for patients with SSc is still unknown. Some observations 
regarding collagen metabolism suggest that a clinical trial duration of 24 weeks or longer 
might be recommended. Indeed, in the phase 2 tocilizumab data (20), the 2-gene biomarker 
was able to differentiate TCZ from placebo at 24 weeks. The biomarkers in clinical trials of 
SSc have shown to correlate with skin fibrosis (as seen here) rather than predict skin 
progression. In addition, the collagen turnover (which is a product of collagen production and 
collagen degradation) may require several weeks to be modulated and this also depends 
whether the pharmacologic agent directly (e.g. Anti-TGF-beta inhibitor) or indirectly (current 
inhibitor) target collagen products. A longer trial with clinical and biological outcome 
measures at 4-6 months may have shown statistically significant differences in this trial.  
 
This study demonstrates that LPA1 blockade by SAR100842 is well tolerated in early dcSSc 
patients. The results show target engagement with SAR100842 and some promising clinical 
and biological changes. Nevertheless, skin fibrotic biomarkers cannot infer treatment effect 
but may be informative as shown in other recent trials (20-22).  Altogether these results 
suggest the potential clinical benefit of SAR100842 in dcSSc patients for whom unmet 
needs remain (23) and deserve its evaluation in confirmatory trials.  
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Legends of the figures:  
Figure 1: Box plot for mRSS change from baseline to Week 8 on mITT population. 
 
Figure 2:  Boxplots for Skin fibrosis markers (changes from baseline to week 8) 
 
Figure 3: Boxplots for Skin fibrosis 4 gene-biomarkers (changes from baseline to week 8) 
 
Figure 4: Boxplots for LPA pathway markers (changes from baseline to week 8) 
 
Figure 5: Boxplots of change in Pathway Activation Index (PAI) from baseline to EOT Week 
8 by treatment groups 
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Table 1: Baseline characteristics 
 
 Placebo 
(n=17) 
SAR100842 
(n=15) 
All  
(n=32) 
Age (years): mean (SD) 50.6 (11.3) 48.8 (10.3) 49.8 (10.7) 
Sex: n (%) female 12 (71%) 9 (60%) 21 (66%) 
Race: n (%) Caucasian/white 13 (76%) 13 (87%) 26 (81%) 
Weight (kg): mean (SD) 70.6 (16.8) 75.1 (19.3) 72.7 (17.9) 
Smokers: current n (%)  3 (18%) 2 (13%) 5 (16%) 
Disease duration (months): mean (SD) 19.6 (7.4) 20.4 (8.9) 20.0 (8.0) 
Raynaud’s phenomenon: n (%) 17 (100%) 14 (93%) 31 (97%) 
Digital ulcers (past or current): n (%) 6 (35%) 4 (27%) 10 (31%) 
Joint synovitis: n (%) 5 (29%) 4 (27%) 9 (28%) 
Tendon friction rubs: n (%) 6 (35%) 7 (47%) 13 (41%) 
Renal crisis: n (%) 1 (6%) 0 1 (3%) 
Dyspnoea (significant) : n (%) 7 (41%) 2 (13%) 9 (28%) 
Fibrosis on plain x-ray: n (%) 3 (18%) 1 (7%) 4 (13%) 
Positive anti-centromere abs: n (%) 1 (6%) 0 1 (3%) 
Positive anti-Scl70 abs: n (%) 5 (29%) 4 (27%) 9 (28%) 
Positive anti-RNA pol III abs: n (%) 4 (24%) 8 (53%) 12 (38%) 
Baseline mRSS:  
mean (SD) 
Median: min-max 
 
24.8 (7.8) 
23 (15-38) 
 
22.7 (8.2) 
21 (15-44) 
 
23.8 (7.9) 
22 (15-44) 
Baseline HAQ-DI:  
mean (SD) 
Median: min-max 
 
1.27 (0.75) 
1.25 (0.0-2.5) 
 
1.23 (0.77) 
1.38 (0.0-2.4) 
 
1.25 (0.75) 
1.37 (0.0-2.5) 
Any prior immunosuppressive or steroid medications  14 (82%) 10 (67%) 24 (75%) 
Mycophenolate mofetil 
Methotrexate 
Systemic steroids 
Topical steroids 
5 (29%) 
9 (53%) 
8 (47%) 
1 (6%) 
7 (47%) 
1 (7%) 
6 (40%) 
1 (7%) 
12 (38%) 
10 (31%) 
14 (44%) 
2 (6%) 
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Table 2: Absence of correlation between change in 4 genes biomarkers and change in 
mRSS  
 
 
 
  
GENE Corr.ch.gene_ch.mRSS Correlation.Pvalue
COMP 0.011 0.96
TSP1 0.0074 0.97
SIGLEC1 0.043 0.82
IFF44 -0.031 0.87
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